Overview

A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients

Status:
Completed
Trial end date:
2018-04-25
Target enrollment:
Participant gender:
Summary
The main study objective is to assess the effect of ACT-709478 in male and female subjects with photosensitive epilepsy following single dose administration
Phase:
Phase 2
Details
Lead Sponsor:
Actelion
Idorsia Pharmaceuticals Ltd.
Treatments:
ACT-709478